ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
The media relations efforts from Alliance staff and researchers are designed to alert the public about the vital work happening across our network. When we share stories about clinical trial results, scientific milestones, and investigator achievements, we are showcasing the real-world progress you help make possible. See where the Alliance was mentioned in October 2026…
Research progress in breast cancer is saving lives, improving treatments, and offering hope to millions of people. Yet breast cancer remains a significant public health challenge, underscoring the continued need for research, earlier detection, and more effective treatment options. Breast cancer is the most common cancer in American women, after skin cancers, accounting for about…